Neoadjuvant treatment for intermediate/high-risk HER2-positive and triple-negative breast cancers: no longer an ‘option’ but an ethical obligation

Lignende værker

• Neoadjuvant treatment: the future of patients with breast cancer
  af: Reyal, F, et al.
  Udgivet: (2018)
• What is the real impact of estrogen receptor status on the prognosis and treatment of HER2-positive early breast cancer?
  af: Brandão, Mariana, et al.
  Udgivet: (2020)
• Are we HER-ting for innovation in neoadjuvant breast cancer trial design?
  af: Snoj, Natasa, et al.
  Udgivet: (2009)
• A Stromal Immune Module Correlated with the Response to Neoadjuvant Chemotherapy, Prognosis and Lymphocyte Infiltration in HER2-Positive Breast Carcinoma Is Inversely Correlated with Hormonal Pathways.
  af: Anne-Sophie Hamy, et al.
  Udgivet: (2016-01-01)
• A Stromal Immune Module Correlated with the Response to Neoadjuvant Chemotherapy, Prognosis and Lymphocyte Infiltration in HER2-Positive Breast Carcinoma Is Inversely Correlated with Hormonal Pathways
  af: Hamy, Anne-Sophie, et al.
  Udgivet: (2016)